Characterization of the Mechanisms of Resistance to Azacitidine

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Sep 27, 2010

Keywords

ClinConnect Summary

This clinical trial is studying how certain blood cancers, specifically myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with multiple lineage dysplasia, respond to a treatment called Azacitidine. The researchers want to understand how Azacitidine works to kill cancer cells and why some patients might not respond well to it. They are particularly interested in two processes: apoptosis (a form of programmed cell death) and autophagy (a process where cells clean out damaged parts). Additionally, the study aims to explore if using other drugs can help overcome resistance to Azacitidine.

To be eligible for this trial, participants need to be at least 18 years old and diagnosed with high-risk MDS or AML. They should have already received at least three to six cycles of Azacitidine treatment. The study is currently recruiting participants of all genders. If you choose to participate, you will contribute to important research that could improve treatment options for others facing these serious conditions. Your involvement will help scientists learn more about how to fight these cancers effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • High Risk or Intermediate 2 MDS (IPSS)
• • AML-MD (WHO classification)
• • Treatment with minimum three to six cycles of Azacitidine
• • Informed consent form signed
• Exclusion Criteria:
• • Treatment with others chemotherapies alone or in association